{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:35:18Z","timestamp":1792146918998,"version":"4.4.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2002,10]]},"DOI":"10.1007\/s11912-002-0030-2","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T15:06:48Z","timestamp":1180710408000},"page":"375-380","source":"Crossref","is-referenced-by-count":10,"title":["Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia"],"prefix":"10.1007","volume":"4","author":[{"given":"Edward A.","family":"Stadtmauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"30_CR1","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","volume":"93","author":"EL Sievers","year":"1999","unstructured":"Sievers EL, Appelbaum RT, Spielberger SJ, et al.: Selected ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999, 93:3678\u20133684.","journal-title":"Blood"},{"key":"30_CR2","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","volume":"19","author":"EL Sievers","year":"2001","unstructured":"Sievers EL, Larson RA, Stadtmauer EA, et al.: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001, 19:3244\u20133254. Summary of the phase II trials of GO in first-relapse AML showed its efficacy and toxicity in 142 patients and led to FDA approval.","journal-title":"J Clin Oncol"},{"key":"30_CR3","first-page":"301a","volume":"20","author":"EA Stadtmauer","year":"2001","unstructured":"Stadtmauer EA, Larson RA, Sievers EL, et al.: An updated report of the efficacy and safety of gemtuzumab ozogamicin in 188 patients with acute myeloid leukemia in first relapse [abstract]. Proc ASCO 2001, 20:301a.","journal-title":"Proc ASCO"},{"key":"30_CR4","first-page":"302a","volume":"20","author":"EL Sievers","year":"2001","unstructured":"Sievers EL, Larson RA, Estey E, et al.: Update of prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin followed by hematopoietic stem cell transplantation [abstract]. Proc ASCO 2001, 20:302a.","journal-title":"Proc ASCO"},{"key":"30_CR5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/sj.leu.2401568","volume":"14","author":"EH Estey","year":"2000","unstructured":"Estey EH: Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 2000, 14:476\u2013479.","journal-title":"Leukemia"},{"key":"30_CR6","first-page":"1083","volume":"21","author":"S Durrant","year":"2002","unstructured":"Durrant S, Schuster MW, Linkesch W, et al.: Preliminary report of the safety and efficacy of gentuzumab ozogamicin (Mylotarg) given in combination with cytarabine in patients with acute myeloid leukemia (AML) [abstract]. Proc ASCO 2002, 21:1083.","journal-title":"Proc ASCO"},{"key":"30_CR7","first-page":"4500a","volume":"98","author":"E DeAngelo","year":"2001","unstructured":"DeAngelo E, Russo D, Castaigne S, et al.: Preliminary report of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg) given in combination with cytarabine and daunorubicin in patients with acute myeloid leukemia [abstract]. Blood 2001, 98:4500a.","journal-title":"Blood"},{"key":"30_CR8","first-page":"587a","volume":"98","author":"S Amadori","year":"2001","unstructured":"Amadori S, Willemze R, Suciu S, et al.: Sequential administration of gemtuzumab ozogamicin (GO) and intensive chemotherapy for induction in previously untreated patients with AML over the age of 60: interim results of the EORTC Leukemia Group AML-15A phase II trial [abstract]. Blood 2001, 98:587a.","journal-title":"Blood"},{"key":"30_CR9","doi-asserted-by":"crossref","first-page":"720a","DOI":"10.1182\/blood.V98.13.3575","volume":"98","author":"E Estey","year":"2001","unstructured":"Estey E, Cortes J, Thall P, et al.: Mylotarg +\/-IL-11 in patients age 65 with newly-diagnosed AML\/MDS: comparison with idarubicin + ARA-C [abstract]. Blood 2001, 98:720a.","journal-title":"Blood"},{"key":"30_CR10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","volume":"92","author":"FJ Giles","year":"2001","unstructured":"Giles FJ, Kantarjian HM, Kornblau S, et al.: Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001, 92:406\u2013413. This retrospective review of 119 patients treated at MDACC with CD33+ leukemia receiving GO found 14% incidence of venoocclusive disease, mostly fatal. Most patients received GO in combination with other agents. Combination therapy with GO should be used with great caution only in the context of clinical trials.","journal-title":"Cancer"},{"key":"30_CR11","doi-asserted-by":"crossref","first-page":"766a","DOI":"10.1182\/blood.V98.13.3575","volume":"98","author":"E Estey","year":"2001","unstructured":"Estey E, Giles J, Cortes D, et al.: Gemtuzumab ozogamicin (\u2018Mylotarg\u2019) in untreated acute promyelocytic leukemia [abstract]. Blood 2001, 98:766a.","journal-title":"Blood"},{"key":"30_CR12","first-page":"124a","volume":"98","author":"EA Stadtmauer","year":"2001","unstructured":"Stadtmauer EA, Larson R, Sievers E, et al.: Analysis of predisposing factors for hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (Mylotarg, CMA-676) [abstract]. Blood 2001, 98:124a.","journal-title":"Blood"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-002-0030-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-002-0030-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-002-0030-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T16:49:30Z","timestamp":1587574170000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-002-0030-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["30"],"URL":"https:\/\/doi.org\/10.1007\/s11912-002-0030-2","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}